Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

GSK’s Stevenage site set to become science campus

by Alex Scott
July 23, 2021 | A version of this story appeared in Volume 99, Issue 27

 

GlaxoSmithKline aims to sell almost one-third of its 370,000 m2 R&D site in Stevenage, England, so that the land can be transformed into a biotech science campus. GSK says the plan could unlock up to $470 million of private investment and create up to 5,000 skilled jobs this decade. GSK hopes detailed planning for the campus will begin in 2022. A number of other organizations are already at the site, including the UK government’s Cell and Gene Therapy Catapult and some biotech start-ups.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.